1201 Eastlake Avenue East
Seattle, WA 98102
Phone: 206-442-660

Bruce Carter, president and CEO


ZymoGenetics Inc. is a bioinformatics-driven company dedicated to the discovery and development of novel therapeutic agents used in the treatment and prevention of human illness. The company focuses on protein therapeutics.

Founded in 1981, ZymoGenetics was purchased by Novo Nordisk in 1988 for $30 million cash. Zymogenetics regained its independence from Novo in 2000 and submitted a registration statement to become public in September 2001, completing its IPO in early February 2002, raising $120 million.

Using a product discovery engine comprised of genomics, bioinformatics, molecular biology, protein chemistry and preclinical biology, ZymoGenetics’ strategy to focus on therapeutic proteins research has resulted in five products entering the marketplace. Novo Nordisk collaborations have resulted in Novolin (human insulin), NovoSeven, a Factor VIIa product, and Glugagon for severe hypoglycemia and diagnostic purposes. The company has developed platelet-derived growth factor for diabetic ulcers in collaboration with Johnson & Johhnson and a tissue plasminogen activator sold in Japan.


In September 2001, ZymoGenetics entered into a $52.5 million collaboration with Serono SA for the commercialization of two preclinical product candidates for autoimmune diseases.